PTC, Novartis

PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug for a rare neurological disorder, sending its shares up about 18.5% in premarket trading on Monday.
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Key Takeaways Shares of PTC Therapeutics soared Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.The deal gives Novartis global development,
PTC Therapeutics price target raised to $71 from $47 at UBS
UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program,
Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
Novartis to pay $1 billion upfront to license Huntington’s drug from PTC
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC Therapeutics.
Novartis signs licensing deal worth up to $2.9B with PTC Therapeutics
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
PTC Therapeutics enters global license, collaboration agreement with Novartis
PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease, the companies said in separate Monday statements.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Business Insider14h
PTC Therapeutics price target raised to $32 from $26 at Citi
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, ...
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
6 Analysts Assess PTC: What You Need To Know
Throughout the last three months, 6 analysts have evaluated PTC PTC, offering a diverse set of opinions from bullish to ...
Business Insider1d
PTC Therapeutics: Strategic Partnerships and Financial Strength Drive Buy Rating
In a report released yesterday, Eric Joseph from J.P. Morgan maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price target of $62.00. Don't Miss our Black Friday Offers: ...